Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2017

View Archived Issues

Lilly initiates phase I trial of LY-3200882 in solid tumors

GlaxoSmithKline begins first-in-human study of GSK-1795091

Phase II results reported for cabozantinib in patients with carcinoid and pNET

FDA grants breakthrough therapy designation to uniQure's AMT-060 for hemophilia B

Roxadustat meets primary endpoints in two phase III anemia trials in China

Lenvatinib evaluated in patients with RET fusion gene-positive adenocarcinoma of the lung

EMA accepts peramivir MAA from BioCryst

Incyte and Calithera Biosciences enter global collaboration to develop and commercialize CB-1158

Ocera reports topline data from STOP-HE phase IIb study

Exelixis and Takeda sign exclusive licensing agreement for cabozantinib in Japan

European Commission approves Votubia to treat refractory partial-onset seizures associated with TSC

TiGenix initiates phase Ib/IIa trial of Cx-611 to treat sepsis in community-acquired pneumonia

MJFF awards grants to Addex and Neuropore to support Parkinson's research

Sebia and Janssen sign agreement for IVD test for multiple myeloma

Carna Biosciences and EpiBiome establish research collaboration

Sumitomo Dainippon Pharma recaps highlights of third quarter of fiscal 2016

Enteris BioPharma licenses oral drug delivery technologies to Ferring

Preliminary phase I/II results for tosedostat plus capecitabine in metastatic PDAC

Enanta Pharmaceuticals divulges novel hepatitis B antiviral agents

Advenchen Laboratories identifies new PI3K/mTOR inhibitors

Merck & Co. presents novel cholesterol ester transfer protein inhibitors

AbbVie updates development progress of fourth quarter 2016

Aurigene Discovery Technologies discovers IRAK-4 inhibitors

SERPINC1 and FGB gene polymorphisms as prognostic biomarkers in patients with mCRC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.